89 completed, 18 terminated, 5 recruiting, 5 unknown. 29 Phase 2, 24 Phase 4, 23 Phase 3, 11 Not applicable, 11 Phase 1.
Follow Relapsing-remitting Multiple Sclerosis: new trials by email Literature Review of Relapsing-remitting Multiple Sclerosis trials Research Report on Relapsing-remitting Multiple Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS) Ocrelizumab co-formulated with rHuPH20 - Relapsing-remitting Multiple Sclerosis | Phase 2 | Not yet recruiting | Hoffmann-La Roche | 25 | 2026-10-30 | 2026-10-14 |
| Non-interventional Study of Subcutaneous Ocrelizumab in Persons With Relapsing-Remitting Multiple Sclerosis Ocrelizumab - Relapsing-Remitting Multiple Sclerosis | Recruiting | Hoffmann-La Roche | 1800 | 2026-09-30 | 2026-09-28 | |
| The HIt HArd and hiT Early in Multiple Sclerosis Trial Sequential treatment with rituximab and cladribine - Relapsing-remitting Multiple Sclerosis | Phase 2 | Recruiting | Uppsala University | 60 | 2026-09-01 | 2026-10-22 |
| A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis CT-P53, US-Ocrevus, EU-Ocrevus - Relapsing-remitting Multiple Sclerosis | Phase 3 | Recruiting | Celltrion | 512 | 2024-01-11 | 2024-05-22 |
| Educational Kinesiology Program's Effect on Cognition, Manual Dexterity and Bimanual Coordination in MS Patients educational kinesiology training program intervention for study group, conventional upper extremities coordination training for both arms experimental and comparator (study and control) groups - Relapsing-remitting Multiple Sclerosis | Not applicable | Completed | Cairo University | 36 | 2024-01-10 | 2025-06-03 |
| RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis. Perfusion of treatment Rituximab, Perfusion of treatment Ocrelizumab - Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis | Phase 3 | Recruiting | Rennes University Hospital | 386 | 2023-06-01 | 2026-02-02 |
| WEBCAMS: Walking Exercise for Brain and Cognition in Adults With Multiple Sclerosis GEMS Plus, GEMS - Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis | Phase 1 | Active not recruiting | Kessler Foundation | 31 | 2023-02-01 | 2026-08-06 |
| Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies Relapsing Multiple Sclerosis, Clinically Isolated Syndrome | Completed | Novartis | 326 | 2022-10-11 | 2024-07-29 | |
| A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS) Ocrelizumab, Ocrelizumab Placebo, Fingolimod - Relapsing-remitting Multiple Sclerosis | Phase 3 | Active not recruiting | Hoffmann-La Roche | 188 | 2022-05-19 | 2026-07-15 |
| A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation Ofatumumab, Disease modifying treatment (DMT) - Relapsing-Remitting Multiple Sclerosis | Phase 4 | Active not recruiting | Novartis Pharmaceuticals | 136 | 2022-03-02 | 2026-05-29 |
| Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt Fingolimod - Relapsing-Remitting Multiple Sclerosis | Completed | Hikma Pharmaceuticals LLC | 30 | 2022-01-19 | 2024-08-23 | |
| Understanding the 'Durable Effect' Concept of B-cell Modulating Therapies Anti-CD20 antibody - Relapsing-remitting Multiple Sclerosis | Recruiting | Heinrich-Heine University, Duesseldorf | 100 | 2021-10-27 | 2025-09-18 | |
| Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial Autologous Hematopoietic Stem Cell Transplantation, Ocrelizumab, Alemtuzumab - Relapsing-Remitting Multiple Sclerosis | Phase 2 | Terminated | Universitätsklinikum Hamburg-Eppendorf | 1 | 2021-08-27 | 2022-03-16 |
| Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS) Relapsing-Remitting Multiple Sclerosis | Completed | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 116 | 2021-08-11 | 2024-12-18 | |
| Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen Kesimpta - Relapsing-remitting Multiple Sclerosis, Active Secondary Progressive Multiple Sclerosis | Completed | Novartis Pharmaceuticals | 367 | 2021-06-30 | 2025-11-28 | |
| Dendritic Cells Therapy Combined With Immunomodulatory Treatment in Multiple Sclerosis Autologous peripheral blood differentiated adult tolerogenic dendritic cells expanded, Placebo - Relapsing-Remitting Multiple Sclerosis | Phase 2 | Active not recruiting | Judit Pich | 45 | 2020-01-27 | 2026-02-19 |
| Study of Evobrutinib in Participants With RMS Evobrutinib, Avonex®, Avonex® matched Placebo - Relapsing-remitting Multiple Sclerosis | Phase 3 | Terminated | EMD Serono Research & Development Institute, Inc. | 1 | 2019-09-10 | 2021-08-05 |
| Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS) Evobrutinib, Avonex®, Avonex® matched Placebo - Relapsing-remitting Multiple Sclerosis | Phase 3 | Terminated | EMD Serono Research & Development Institute, Inc. | 3 | 2019-08-26 | 2021-08-05 |
| PET with [18F]Flumazenil As an Index of Neurodegeneration in MS PET with [11C]Flumazenil - Multiple Sclerosis, Relapsing-Remitting Multiple Sclerosis | Not applicable | Completed | Institut National de la Santé Et de la Recherche Médicale, France | 45 | 2019-05-02 | 2025-03-05 |
| Behavior and Activity Monitoring in MS Step Tracking, Water Tracking - Relapsing-Remitting Multiple Sclerosis | Not applicable | Completed | Ohio State University | 87 | 2017-11-02 | 2023-03-24 |
Showing 20 of 127. Sign in to see all of them.
Multiple Sclerosis, Relapsing-Remitting (127) · Multiple Sclerosis (61) · Multiple Sclerosis, Chronic Progressive (8) · Recurrence (6) · Cognitive Dysfunction (3) · Demyelinating Diseases (3) · Fatigue (3) · Nerve Degeneration (3) · Motor Activity (2) · Nervous System Diseases (2) · Sclerosis (2) · Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Demyelinating Autoimmune Diseases, CNS (1) · Depression (1)
Autoimmune Diseases (126) · Autoimmune Diseases of the Nervous System (126) · Demyelinating Autoimmune Diseases, CNS (126) · Immune System Diseases (126) · Nervous System Diseases (125) · Demyelinating Diseases (124) · Multiple Sclerosis (66) · Pathological Conditions, Signs and Symptoms (25) · Pathologic Processes (18) · Disease Attributes (15) · Chronic Disease (8) · Signs and Symptoms (7) · Behavior (3) · Cognition Disorders (3) · Mental Disorders (3)
Interferon beta-1a (19) · Natalizumab (17) · Dimethyl Fumarate (16) · Fingolimod Hydrochloride (9) · Glatiramer Acetate (8) · daclizumab HYP (6) · ocrelizumab (5) · Interferon beta-1b (4) · Alemtuzumab (3) · Daclizumab (3) · Methylprednisolone (3) · evobrutinib (3) · Cladribine (2) · Rituximab (2) · Standard of Care (2)
Biogen (42) · Novartis Pharmaceuticals (8) · EMD Serono Research & Development Institute, Inc. (5) · Tanabe Pharma Corporation (5) · Merck KGaA, Darmstadt, Germany (4) · Charite University, Berlin, Germany (3) · Genzyme, a Sanofi Company (3) · Hoffmann-La Roche (3) · Teva Branded Pharmaceutical Products R&D, Inc. (3) · Bayer (2) · Claudio Gobbi (2) · EMD Serono (2) · Nantes University Hospital (2) · Neurognostics (2) · Novartis (2)
United States (43) · Germany (35) · Czechia (24) · France (24) · Poland (24) · United Kingdom (24) · Italy (22) · Canada (21) · Spain (21) · Russia (18) · Switzerland (18) · Belgium (16) · Ukraine (16) · Hungary (14) · Serbia (13)
Dr. Norbert Zessack (3) · Antonio Fiaschi, Professor (2) · Alexey Boyko, MD (1) · Alla Bru, MD (1) · Anders Svenningsson, MD, PhD (1) · Anna Fogdell-Hahn, PhD (1) · Annette Langer-Gould, MD, PhD (1) · Annette Wundes, MD (1) · Antonie G. Beiske, MD (1)
PMID 27411694, PMID 26932146, PMID 27733070, PMID 30918100, PMID 32426039, PMID 24131282, PMID 26526385, PMID 28751099, PMID 28770420, PMID 37061656, PMID 18789766, PMID 20089952, PMID 20542736, PMID 20737510, PMID 20737514, PMID 22065170, PMID 22494956, PMID 22507886, PMID 22751847, PMID 22992072, PMID 22992073, PMID 23531349, PMID 23555589, PMID 23562009, PMID 23595275, PMID 23764350, PMID 23915113, PMID 24011220, PMID 24378984, PMID 24497963, PMID 24531550, PMID 24532785, PMID 24576156, PMID 24656609, PMID 24898925, PMID 25245812, PMID 25315404, PMID 25416807, PMID 25546364, PMID 25583852, PMID 25755648, PMID 25876471, PMID 26049148, PMID 26083135, PMID 26121423, PMID 26195058, PMID 26392348, PMID 26444729, PMID 26563147, PMID 27090116
2014 (4), 2008 (3), 2009 (3), 2018 (2), 2005 (1), 2016 (1), 2023 (1), 2025 (1)